Logo

Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Share this
Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Shots:

  • The companies have completed the enrolment in P-II AKI-002-15 study evaluating the safety and efficacy of ANG-3777 (2.0 mg/kg- IV) vs PBO over 4 days in patients with CSA-AKI across the US- Canada- Brazil- and Georgia
  • The first dose was given within 4hrs. of the completion of surgery with subsequent doses @24hrs. interval. The 1EP is an increased percentage of serum creatinine above baseline- starting from 24hrs. after the end of cardiopulmonary bypass surgery through day 6.
  • The companies plan to initiate confirmatory trial early in 2022- following the results of P-II study as well as discussions with the FDA and other relevant health authorities. The topline data is expected in H2’21

  Ref: Globe Newswire | Image: Linkedin

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions